/Investor DB

aMoon — 2021 Investments

5 investments dated 2021 · listed companies and verified rows first · show all

Sera Prognosticsseraprognostics.comin𝕏NASDAQ: SERAApr 2021 · $100M

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in

BoardMansoor Mirza(Director)

Co-investorsExcelestar VenturesIntermountain HealthOUP (Osage University Partners)UpStart VenturesVivo CapitalCatalyst Health Ventures+1 more

Scipher Medicinesciphermedicine.comin𝕏Series C · Mar 2021 · $82M✓ verified

Scipher Medicine is a precision immunology company that combines molecular data from autoimmune patients, protein interaction mapping, and AI to match patients with the most effective therapy for immunological diseases.

AI & Machine LearningBiotechDigital Health

Joseph Loscalzo(Founder)Albert-László Barabási(Founder)

Co-investorsKhosla VenturesAlumni VenturesB3 HoldingCobalt VenturesEcho Health VenturesHitachi Ventures+2 more

AltruBioaltrubio.comSeries A · Apr 2021 · $63M

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsDelos CapitalRA CapitalBiotechnology Value FundSoleus Capital

Kahrkahrbio.comJun 2021 · $47M

Uses proprietary technology to unmask cancer and recruit a targeted immune response.

Co-investorsCancer FocusPeregrine Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Biosplice Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.